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Abstract: Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology. The majority of
individuals with RA are positive for the disease-specific anti-citrullinated protein antibodies (ACPAs).
These antibodies are primarily of cross-reactive nature, hence, the true autoantigen to ACPA remains
unidentified. In this study, we analyzed the reactivity of RA sera to several post-translationally
modified epitopes, in order to further characterize the specific nature of ACPAs by immunoassays.
Substituting citrulline with other amino acids, e.g., D-citrulline, homo-citrulline and methyl-arginine
illustrated that ACPAs are utmost specific for citrullinated targets. Collectively, these findings support
that ACPAs and citrullinated targets are specific for RA, making citrulline-containing peptide targets
the most effective assays for detection of ACPAs.
Keywords: anti-citrullinated protein antibodies; citrulline; homo-citrulline; epitopes; peptides;
rheumatoid arthritis
1. Introduction
Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, which causes
inflammation in the joints and in severe cases erosion of the underlying bone [1]. The disease
primarily affects women with a 2:1 female/male ratio and onset of disease symptoms typically peak in
the forties to sixties [2]. The disease affects approximately 1% of the population worldwide [1,3].
Several autoantibodies are associated with RA. One of the most known is the rheumatoid factor
(RF), which recognizes the fragment crystallizable (Fc) domain of IgGs, that is the second and third
constant regions of IgG. Although present in 60%–70% of individuals with RA, this group of antibodies
is not specific for RA as RF also occasionally is detected in other connective tissue diseases [4,5].
Another group of antibodies that is associated with RA is the anti-citrullinated protein antibodies,
also referred to as ACPAs. ACPAs recognize the post-translationally modified amino acid citrulline,
originating from the amino acid arginine [6,7]. The peptidylarginine deiminase (PAD) catalyzes the
conversion of arginine to citrulline, where the nitrogen atom is replaced with an oxygen atom and the
positive charge of the guanidino group is eliminated [8].
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ACPAs are detected in up to 80% of serum from RA individuals and have been reported to be
associated with a more severe disease course and disease outcome compared to ACPA-negative RA,
and may even precede disease symptoms [9–12]. These antibodies are specific for RA, although they
also have been sporadically reported to be associated with other diseases [13].
Several antibody-based assays exist for detection of ACPAs. The majority of the assays employ
cyclic citrullinated peptides (CCP) [12,14–16]. Dependent on the origin of the assays and the number
of peptides, the assays are divided into three generations, CCP1–CCP3 [9,12,14–16]. The assays
employ different peptides, indicating that the presence of citrulline, rather than a specific citrullinated
epitope itself, is essential for ACPA detection, which is in accordance with their cross-reactive nature.
ACPAs recognize several citrullinated protein targets, preferably with a Cit–Gly motif [7,17–21].
Although no true citrullinated autoantigen has been identified, several citrullinated targets have been
reported, e.g., collagen, fibrinogen, Epstein-Barr nuclear antigen (EBNA)-1, EBNA-2, α-enolase, and
vimentin [18,22–27]. As a consequence, ACPAs have been described as a group of antibodies with
overlapping reactivity, characterized by significant cross-reactivity to citrullinated targets [24,25,28,29].
Several studies have analyzed the importance of the amino acids surrounding citrulline for a stable
antibody–antigen interaction. Studies find that the Cit–Gly motif is essential for antibody reactivity,
although other motifs occasionally are tolerated as well [17,20,21]. Substitution studies illustrate that
substitutions in positions –x–x–Cit–G–x– have no influence on antibody reactivity, clearly illustrating
the importance of the central Cit–Gly motif rather than a specific epitope, which the majority of antigens
demonstrate [17,19–21,23]. However, only limited information is available in relation to modification
of the specific amino acid citrulline.
It has been reported that ACPAs occasionally may interact with homo-citrullinated peptides
as well [30]. Homo-citrulline is similar to citrulline, a post-translational modification of arginine.
The functional group of homo-citrulline and citrulline is identical, but the carbon backbone of
homo-citrulline contains and additional -CH2- compared to citrulline. Antibodies recognizing
citrulline- and homo-citrulline-containing peptides contain partly overlapping binding sites in RA sera,
suggesting some kind of relationship between these two groups of antibodies [31–33]. The relationship
between homo-citrulline and RA remains unclear.
In the present study, we examined the importance of the specific citrulline unit in order to
obtain further knowledge about the nature of citrulline-dependent antibody–antigen interactions and
ACPA response in RA patients. This was done by substituting citrulline with amino acids of similar
functionality, e.g., D-citrulline, homo-citrulline, methyl-arginine, and arginine, and analyzing antibody
reactivity in traditional immunoassays. We found that antibody reactivity was significantly reduced
when citrulline was substituted with D-citrulline, homo-citrulline, or methyl arginine. These findings
illustrate that the presence of L-citrulline is crucial for specific antibody reactivity, and even the
smallest alterations in the amino acid side chain or side chain presentation interferes with the specific
antibody–antigen interaction.
2. Materials and Methods
2.1. Materials
Synthetic citrulline-, arginine- and homo-citrulline-containing peptides were from Schafer-N
(Lyngby, Denmark). Streptavidin, alkaline phosphatase (AP)-conjugated goat anti-human IgG and
para-nitrophenylphosphate (pNPP) were from Sigma Aldrich (St. Louis, Mo, USA). Tris–Tween–NaCl
(TTN) buffer (0.05 M Tris, 0.3 M NaCl, 1% Tween 20, pH 7.4) and AP-substrate buffer (1 M diethanolamine,
0.5 mM MgCl2, pH 9.8) were from SSI Diagnostica (Hillerød, Denmark).
2.1.1. Patient Sera
Twenty-five RA-positive sera, diagnosed according to the American College of Rheumatology
(ACR) classification criteria [34] were enrolled in this study. The sera were obtained from Rigshospitalet
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Glostrup. The project was approved by the scientific ethics committees in Denmark (Project ID: 19980024
PMC and H-15009640). Healthy control (HC) sera were obtained from volunteers at Rigshospitalet
and at Statens Serum Institut (Copenhagen, Denmark). All participating subjects gave their written
informed consent for inclusion before they participated in the study. Twenty-five RA sera were enrolled
of which 22 were from females. The average age for RA patients was 55 years. All RA sera were
CCP2 positive, with CCP titers ranging from 25 to 3200 U/mL. Eighteen RA sera were RF IgA positive
(>15 U/mL) and 21 were RF IgM positive (15 IU/mL). Three sera were RF negative.
2.1.2. Synthetic Peptides
Synthetic peptides containing methylarginie were synthesized by traditional fluorenylmethyloxyc
arbony peptide synthesis, as previously described [35]. The peptides were approximately 20 amino
acids long with a central Cit/hCit/Arg (Nω−Me)/Arg residue. The modified amino acids introduced
are presented in Figure 1.
Figure 1. Schematic illustration of the central amino acid substitutions found in the peptides used in
this study. The point of origin is citrulline; the circles represent atoms different from citrulline.
As presented in Table 1, the peptides selected for analysis in this study were a combination of
human proteins and viral proteins, which have previously been identified as potential ACPA targets.
In particular, the citrullinated viral EBNA-2 peptide and the human pro-filaggrin peptide have been
reported to be good ACPA substrates [7,12,24,25]. Thus, ACPA reactivity was analyzed based on
reactivity to human peptides and cross-reactivity to viral peptides.
Table 1. Peptides used in the current study. The underscored amino acids represent the substituted
amino acid.
Peptide aa Origin Substitution
SHQEST–R–GRSRGRS 306–319 Profilaggrin Cit
HQSHQEST–R–GRSRGRSGRSGS 304–324 Profilaggrin Cit/hCit
GSGGRGRGGSGGRRG–R–GRER 341–360 EBNA1 Cit/hCit
ARGGSRERARGRGRG–R–GEKR 361–380 EBNA1 Cit/hCit/Arg(Me)
GNGLGE–R–GDTSGPEGSGGSG 11–30 EBNA1 Cit/hCit
GRGRGRGE–R–RPRSPSSQSSS 371–390 EBNA1 Cit/hCit
FAEVLKDAI–R–DLVMTKPAPT 571–590 EBNA1 Cit/hCit
GGSKTSLYNLR–R–GTALAIPQ 511–530 EBNA1 Cit/hCit/Arg(Me)
PQASVPLRLT–R–GSRAPISRAQ 1835–1855 Proteoglycan Arg(Me)
GQGRGRWRG–R–GRSKGRGRMH 313–332 EBNA-2 Arg(Me)
2.2. Streptavidin Capture Enzyme-Linked Immunosorbent Assay
MaxiSorp 96-well microtiter plates (Nunc, Roskilde, Denmark) were precoated with streptavidin
(1 µg/mL) for 2 h at room temperature (RT) followed by coating with biotinylated peptides (1µg/mL)
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for 2 h at RT. Sera diluted (1:200) in TTN were added to the microtiter plates and incubated for 1 h at
RT. Patient sera were analyzed in duplicates. After careful washing with TTN buffer, AP-conjugated
goat anti-human IgG diluted in TTN (1 µg/mL) was added to the wells and the plates incubated for 1 h
at RT. For antibody quantification, AP activity was determined with pNPP (1 mg/mL) diluted in AP
substrate buffer. The absorbance was measured at 405 nm, with background subtraction at 650 nm,
using a ThermoMax microtiter plate reader (Molecular Devices, Menlo Park, CA, USA).
2.3. Statistical Analyses
Statistical calculations were performed using two measurements of 25 RA sera. The values
obtained in this study were compared further by using the two-tailed Student’s t-test for single column
analysis and Mann–Whitney U-test, which compared all columns to control columns.
3. Results
3.1. Reactivity of Rheumatoid Arthritis Sera to D/L-Citrulline-Containing Peptides
To determine whether the orientation of citrulline in the epitope is essential for antibody reactivity,
the reactivity of ACPA-positive RA sera was analyzed to two peptides (SHQEST-Cit-GRSRGRS),
originating from pro-filaggrin by streptavidin capture enzyme-linked immunosorbent assay (ELISA).
The pro-filaggrin peptide, SHQEST-R-GRSRGRS, was selected for preliminary analysis, as a peptide
containing this central region originally was used for detection of ACPAs. One peptide version
contained a traditional L-citrulline, whereas the other contained D-citrulline. In total, 25 RA and 20 HC
sera were analyzed for reactivity.
As presented in Figure 2, the ACPA-positive RA sera reacted with the citrullinated pro-filaggrin
peptides (Figure 2a).
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Figure 2. Antibody reactivity to a citrullinated pro-filaggrin peptide containing D- or L-citrulline
analyzed by streptavidin capture ELISA. The Arg-containing pro-filaggrin, with a natural L-Arg was
used as negative control. (a) Reactivity of RA sera (n = 25); (b) Reactivity of healthy control (HC) sera
(n = 20).
The RA sera reacted with the D-citrulline-containing peptide as well, however, antibody reactivity
was significantly reduced when replacing L-citrulline with D-citrulline (p < 0.0001). None of the HC
sera reacted significantly with the pro-filaggrin peptides (Figure 2b). These findings indicate that the
orientation of the citrulline side chain is crucial for antibody reactivity.
3.2. Reactivity of Rheumatoid Arthritis Sera to Citrullinated and Homo-Citrullinated Peptides
Next, the reactivity of RA sera to various citrullinated and homo-citrullinated epitopes was
analyzed by streptavidin capture ELISA. In total, 10 RA sera and 10 HC sera were analyzed for reactivity.
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Peptides originating from pro-filaggrin and EBNA1 were selected as templates, as Epstein–Barr virus
(EBV) has been proposed to be involved in the onset of RA, and because ACPAs are very cross-reactive.
Some of the EBV peptides have been described as good ACPA candidates, whereas others have been
described as poor candidates. This was done in order to determine whether addition of homo-citrulline
would increase antibody reactivity, and ultimately, to determine whether antibody reactivity to
citrullinated peptides and homo-citrullinated peptides differ from each other.
Figure 3 illustrates the reactivity of RA and HC sera to the substituted peptides.
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Figure 3. Reactivity of rheumatoid arthritis (n = 10) and healthy control sera (n = 10) to substituted
peptides analyzed by streptavidin capture ELISA. (a) Reactivity of RA sera to citrullinated peptides;
(b) Reactivity of RA sera to homo-citrullinated peptides; (c) Reactivity of HC sera to citrullinated
peptides; (d) Reactivity of HC sera to homo-citrullinated peptides; (e) Peptides screened for
analysis, with the statistical difference in antibody reactivity between the individual citrullinated and
homo-citrullinated peptides. Xxx represent the location of the substituted amino acid in the peptide.
Peptide 1: pro-filaggrin (aa 306–319). Peptide 2–7: EBNA-1 derived peptides (see Table 1 for further
information). All modifications replaced the positively charged amino acid arginine.
As presented in Figure 3, significant antibody reactivity occurred with the citrullinated peptides,
compared to the homo-citrullinated peptides (Figure 3a,b,e). The RA sera reacted primarily with
peptide 3 and 6 of the homo-citrullinated analogues (Figure 3b) and peptides 1, 2, 3, 4 and 6 of the
citrullinated analogues (Figure 3a). No reactivity was found to peptide 7, which most likely is due to
the absence of a Gly residue on the C-terminal side of citrulline. The RA sera reacted weakly with the
homo-citrullinated version of peptide 6, and not with the citrullinated version, which most likely is
due to the presence of negatively charged amino acids, which previously have been found to influence
antibody reactivity negatively, when located close to the citrulline residue [17,20]. None of the HC
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sera reacted with the substituted peptides (Figure 3c,d). These findings indicate that antibodies to
homo-citrullinated peptides have the same restrictions as citrullinated peptides.
3.3. Reactivity of Rheumatoid Arthritis Sera to Arg(NwMe) Peptides
Methylation is another posttranslational modification of Arg, which theoretically could be relevant
in relation to autoantibody reactivity. To determine whether Arg(Me) peptides were recognized by
RA sera, selected Arg(Me)-, Arg- and citrulline-containing peptides, which previously have been
identified as potential ACPA substrates, were screened for antibody reactivity by streptavidin capture
ELISA. In total, 20 RA sera were screened for reactivity. Arg–Gly-containing peptides were used as
negative control.
Figure 4 illustrates the reactivity of RA sera to peptides containing either citrulline, Arg(Me)
or arginine. The RA sera reacted significantly with the citrullinated analogues compared to the
arginine-containing control peptides (p < 0.0001). RA reactivity was found in relation to the Arg(Me)
EBNA-1 (Figure 3a) and EBNA-2 peptides (3d), however, reactivity not significant compared to the
controls (Arg-containing peptides). Increased levels of antibody reactivity to Arg(Me)-containing
EBNA may be ascribed to the presence of EBV-specific antibodies. As can be seen, antibody reactivity
was significantly reduced when replacing citrulline with Arg(Me). These findings confirm that the
presence of citrulline is extremely specific and crucial for a stable ACPA interaction.
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Figure 4. Reactivity of rheumatoid arthritis sera (n = 20) to citrullinated and Arg(Me)-substituted
peptides analyzed by streptavidin capture ELISA. (a) Antibody reactivity to substituted
peptides, using the EBNA1 peptide ARGGSRERARGRGRG–R–GEKR as template; (b) Antibody
reactivity to substituted peptides, using the EBNA1 peptide GGSKTSLYNLR–R–GTALAIPQ
as template; (c) Antibody reactivity to substituted peptides, using the proteoglycan peptide
PQASVPLRLT–R–GSRAPISRAQ as template; (d) Antibody reactivity to substituted peptides using the
EBNA2 peptide GQGRGRWRG–R–GRSKGRGRMH as template.
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4. Discussion
Currently, no true autoantigens of RA have been identified, which is attributed to ACPA responses
in RA sera being cross-reactive [20,24,25,28,29]. Based on this knowledge, we, like others, selected viral
peptides in combination with human-derived peptides for characterization of the ACPA response,
because EBV has been proposed to be involved in the onset of RA. Based on current knowledge and the
fact that none of these peptides have been targeted in regular EBV immune responses [25,36], findings
indicate that viral citrullinated peptides are representative of characterization of ACPAs. This is in
accordance with our recent findings where we described that a single viral peptide originating from
EBNA2 is just as effective in detecting ACPAs as the currently applied CCP assays, and more effective
as the originally described pro-filaggrin peptide [12,24].
Antibody reactivity to D-citrulline-, L-citrulline-, homo-citrulline-, and Arg(Me)-containing
peptides was determined. As can be seen, substitution of L-Cit to D-Cit significantly reduced antibody
reactivity (Figure 2), indicating that a correct presentation of the side chain is crucial for a stable
antibody-antigen interaction, which is accordance to several crystal structures of antibody-Cit peptide
complexes [26,37].
A similar pattern applies to experiments analyzing antibody reactivity to citrulline and
homo-citrullinated peptides (Figure 3). Antibody reactivity was significantly reduced to the
homo-citrullinated peptides compared to the citrullinated peptides, most likely because the additional
-CH2- unit in the side chain of homo-citrulline projects the crucial oxygen atom, making it impossible to
generate the crucial hydrogen bond between the antibody and the antigen. This remains to be verified,
by X-ray crystallography. A few citrullinated and homo-citrullinated peptides were not recognized
by the RA sera, which most likely relates to the presence of a negatively charged amino acid close to
(homo-)citrulline (GNGLGE–Xxx–GDTSGPEGSGGSG) (or the absence of a positive charge in position
3–5 C-terminal to citrulline) and the absence of a Cit–Gly motif (FAEVLKDAI–Xxx–DLVMTKPAPT).
These findings indicate that antibodies recognizing homo-citrullinated and citrullinated epitopes have
similar reactivity patterns (or limitations), as previously suggested [33].
It has previously been reported that the mere presence of a peptide backbone and a Cit–Gly
motif is sufficient for antibody recognition [19]. Nevertheless, this most likely only applies if the
side chain of citrulline is projected into the binding groove of the antibody [26]. Thorough studies
performed by Uysal and colleagues characterized the interaction between a monoclonal antibody
directed to a citrullinated collagen peptide (A–Cit–GLTGRPGDA) [26]. Structure analysis showed
that the citrullinated epitope changes conformation upon interaction with the antibody by adopting a
non-native β-hairpin conformation, where the side chain of citrulline is exposed into the combining
site of the antibody [26]. This allows the peptide to have more interactions between the antibody’s
complementarity-determining regions (CDR) and the amino acids side chains of the antigenic peptide,
which contributes to an increased affinity. Moreover, the specific contact with the citrulline residue
(through the crucial oxygen atom) illustrates that an arginine in the same position would not make
contact [26]. This study has been confirmed by a very recent study conducted by Ge and colleagues,
where the crystal structure of an antibody-citrullinated peptide complex was analyzed [37]. They found
that the central Cit–Gly motif in combination with a flexible peptide structure was essential for antibody
reactivity, as only the central motif mediated direct contact with the antibody. Based on these findings,
it was concluded that citrulline specificity can be explained by direct interactions with the antibody.
This model may explain why antibody reactivity is lost when substituting L-citrulline with D-citrulline.
The L-citrulline residue protrudes into the CDRs, making direct contact, however, the side chain of
D-citrulline protrudes away from the CDRs, increasing the distance between the interactive amino
acids in the antibody and antigen. As a consequence, the amino acids are too far apart to generate a
stable interaction. This remains to be verified.
The origin and biological function of citrullinated antigens in RA are unknown. Citrullination
is catalyzed by PAD in a process where the positively charged guanidine group is replaced with the
neutrally charged ureido group by an overall N to O exchange reaction [8]. In RA, Arg-containing
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peptides are candidate antigens for generation of ACPAs. Citrullination arises as a posttranslational
modification in relation to infection or inflammation, and it may be regarded as a cellular response to an
altered cellular state. Likewise, other Arg modifications could possibly arise in response to the altered
cellular state, and methylations are a relatively common modification of Arg, which could play a role
in the development of autoimmunity. Based on this knowledge, antibody reactivity to methylated Arg
peptides was also analyzed. However, as presented in Figure 4, no significant antibody reactivity was
found to the Arg(Me)-substituted peptides. This makes sense, as the crucial oxygen atom in the side
chain of Arg is replaced with nitrogen, which does not contribute with an ionic bond but a hydrogen
bond. Not even the presence of an additional CH3–, which may contribute with additional Van der
Waals interactions may compensate for the displacement of the crucial oxygen atom.
Collectively, these findings illustrate the specific nature of ACPA reactivity to citrullinated targets.
When altering the orientation of citrulline in the binding pocket of the antibody, the antibody reactivity
is significantly reduced, clearly illustrating the “key–lock” approach for antibodies. No modifications
are tolerated, illustrating how fragile, yet strong and specific, antibody–antigen interactions in ACPA
responses are.
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